Advantages and Limitations of Monitoring Circulating Tumor DNA Levels to Predict the Prognosis of Patients Diagnosed With Gastric Cancer. Issue 17 (December 2022)

• Record Type: Journal Article
• Authors: He, Wan; Yang, Jingxin; Sun, Xiao; Jiang, Shunda; Jiang, Jinchan; Liu, Ming; Mu, Tianhao; Li, Yingmei; Zhang, Xiaoni; Duan, Jingxian; Xu, Ruilian
• Is Part Of: Biomarker insights. Volume 2022:Issue 17(2022)
• Publication Date: 2022-12
• Subjects: Gastroenterology -- cfDNA -- molecular characterization -- prognosis -- surveillance; Biochemical markers -- Periodicals; 572.43
• DOI: 10.1177/11772719221141525
• Languages: English
• ISSNs: 1177-2719

Abstract

Next-generation sequencing-based genomic profiling facilitates biomarker detection by cell-free DNA (cfDNA) liquid biopsy. However, the efficiency of mutation calling and the prognostic value of cfDNA biomarkers are disputed. We investigated 24 patients with gastric cancer in this study, using a 605-gene sequencing panel to sequence their plasma cfDNA and tumor tissue DNA. The mutation concordance between plasma cfDNA and tumor tissue DNA was 70.6% in stage IV gastric cancer and 30.2% in stage III gastric cancer, indicating insufficient mutation detection rates in stage III and early-stage cancer. When compared with total cfDNA load and blood tumor mutation burden (bTMB), the variant allele frequencies (VAF) of commonly mutated genes are highly accurate in representing disease burden. Further, VAF are a better prognostic indicator compared with serum biomarkers including carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), cancer antigen 125 (CA125), and alpha-fetoprotein (AFP). The use of cfDNA in molecular profiling of patients allows prediction of patient survival and clinical response, as well as the development of personalized therapy regimens.